Synthesis and in silico evaluation of novel uridyl sulfamoylbenzoate derivatives as potential anticancer agents targeting M1 subunit of human ribonucleotide reductase (hRRM1)-Reference-Cited by-同舟云学术

Synthesis and in silico evaluation of novel uridyl sulfamoylbenzoate derivatives as potential anticancer agents targeting M1 subunit of human ribonucleotide reductase (hRRM1)

Published:2022-01-28 Issue:7 Volume:31 Page:1109-1119
ISSN:1054-2523
Container-title:Medicinal Chemistry Research
language:en
Short-container-title:Med Chem Res

Author:

Salvador Prince J.,Jacobs Heather B.,Alnouri Lujain,Fee Asia,Utley Lynn M.,Mabry Madison,Krajeck Hannah,Dicksion Christopher,Awad Ahmed M.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics

Link

https://link.springer.com/content/pdf/10.1007/s00044-021-02840-4.pdf

Reference48 articles.

1. Greene BL, Kang G, Chang C, Bennati M, Nocera DG, Drennan CL, Stubbe J. Ribonucleotide reductases (RNRs): structure, chemistry, and metabolism suggest new therapeutic targets. Annu Rev Biochem. 2020;89:45–75.

2. Knighton LE, Delgado LE, Truman AW. Novel insights into molecular chaperone regulation of ribonucleotide reductase. Curr Genet. 2019;65:477–82.

3. Brown NC, Reichard P. Ribonucleoside diphosphate reductase: formation of active and inactive complexes of proteins B1 and B2. J. Mol. Biol. 1969;46:39–55.

4. Cotruvo JA, Stubbe JA. Class I ribonucleotide reductases: metallocofactor assembly and repair in vitro and in vivo. Annu Rev Biochem. 2011;80:733–67.

5. Cerqueira NMFSA, Ramos MJ. Ribonucleotide reductase: A critical enzyme for cancer chemotherapy and antiviral agents. Recent Pat Anti-Cancer Drug Discov. 2007;2:11–29.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets;Pharmacology & Therapeutics;2024-02